Thursday, April 3rd, 2025

iFast Corporation: Refuting Short-Seller Claims

iFast Corporation:

  1. Refuting Short-Seller Claims: iFast Corporation has denied claims made in a short-seller report by Sakura Research, which questioned the sustainability of iFast’s Hong Kong ePension division’s revenue, the health of its UK digital bank, and its overall profitability.
  2. Sustained Revenue from ePension Division: iFast asserts that its ePension division in Hong Kong will maintain revenue over a seven-year contract period, despite the short-seller’s prediction of a significant revenue drop after the project’s full implementation in 2025.
  3. Industry Analyst Support: CGS International analyst Andrea Choong and UOB Kay Hian analyst Heidi Mo refuted Sakura Research’s claims, highlighting iFast’s solid financial position and growth prospects, particularly with the upcoming onboarding of additional trustees to the ePension project.
  4. UK Digital Bank Prospects: iFast’s UK digital bank, iFast Global Bank, aims to break even by Q4 2024. Comparisons made by Sakura Research between iFast Global Bank and other digital banks like GXS Bank were deemed unfair by analysts, who noted iFast’s focus on a broader customer base and revenue from loans.
  5. Improved Profitability Metrics: iFast’s profit before tax for the latest half-year stood at S$37.9 million, with a ratio of operating profit to assets under administration (AUA) improving to 0.169%, up from 0.047% in 2023. The decline in 2022 was attributed to impairments and higher operating expenses related to new projects.
  6. Stock Impact: Since the release of the short-seller report on Aug 19, iFast’s shares have fallen by 3% to S$7.07 as of Aug 30, with a year-to-date decline of 13.9%.

Thank you

ASEAN TMT Outlook: Strong Interest in SE, Data Center Concerns, and Telco Picks

Comprehensive Analysis of ASEAN TMT Sector – Maybank Research Comprehensive Analysis of ASEAN TMT Sector Prepared by: Maybank Research Pte Ltd Date: January 22, 2025 Introduction Maybank Research delved into the ASEAN telecommunications and...

“Stoneweg European REIT: Buy Rating, 2025 Insights, and Growth Potential in European Real Estate”

Introduction The comprehensive review provides an in‐depth analysis of Stoneweg European REIT (STON.SI) alongside a detailed comparison with its key peers in the European REIT landscape. The review covers Stoneweg’s stable operating performance, refinancing...

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals 🏢 Sino Biopharmaceutical (1177 HK) – Leading the Charge with Innovative Drug Development Recommendation: BUY Target Price: Not specified Stop Loss: Not...